Massachusetts Society of Clinical Oncologists - FDA approves selinexor (Xpovio) for relapsed/refractory diffuse large B-cell lymphoma

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA approves selinexor (Xpovio) for relapsed/refractory diffuse large B-cell lymphoma

FDA approves selinexor (Xpovio) for relapsed/refractory diffuse large B-cell lymphoma

23 Jun 2020 7:11 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: msco@mms.org